RareCan Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Later Stage VC
- (Upcoming)
- Investors
-
8
RareCan General Information
Description
Developer of a direct-to-patient clinical trial platform designed to improve outcomes for cancer patients. The company's platform develops novel patient and data pipelines, underpinned by proprietary technology, that make it quicker and cheaper for the global pharmaceutical industry to access the patients and data needed to deliver precision medicine trials and accelerate the pace at which new precision medicines are brought to market, enabling researchers to find treatments for cancer and increase the success rate of rare cancer trials for the global cancer drug market.
Contact Information
Website
www.rarecan.comCorporate Office
- 8 Park Avenue
- Hexham NE46 3EN
- England, United Kingdom
Corporate Office
- 8 Park Avenue
- Hexham NE46 3EN
- England, United Kingdom
RareCan Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | Upcoming | Generating Revenue | ||||
| 6. Accelerator/Incubator | 01-Dec-2024 | Completed | Generating Revenue | |||
| 5. Grant | Completed | Generating Revenue | ||||
| 4. Accelerator/Incubator | 08-Nov-2022 | Completed | Generating Revenue | |||
| 3. Seed Round | 28-Jun-2022 | Completed | Generating Revenue | |||
| 2. Seed Round | 19-Mar-2021 | $279K | $279K | Completed | Generating Revenue | |
| 1. Grant | 01-Jan-2021 | $2.68K | Completed | Generating Revenue |
RareCan Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
RareCan Signals
RareCan Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BioIndustry Association | Accelerator/Incubator | |||
| The Francis Crick Institute | Accelerator/Incubator | Minority | ||
| Anglia Angels | Angel Group | Minority | ||
| Cambridge Angels | Angel Group | Minority | ||
| Women Angels | Angel Group | Minority |
RareCan FAQs
-
When was RareCan founded?
RareCan was founded in 2019.
-
Where is RareCan headquartered?
RareCan is headquartered in Hexham, United Kingdom.
-
What is the size of RareCan?
RareCan has 6 total employees.
-
What industry is RareCan in?
RareCan’s primary industry is Discovery Tools (Healthcare).
-
Is RareCan a private or public company?
RareCan is a Private company.
-
What is RareCan’s current revenue?
The current revenue for RareCan is .
-
How much funding has RareCan raised over time?
RareCan has raised $926K.
-
Who are RareCan’s investors?
BioIndustry Association, The Francis Crick Institute, Anglia Angels, Cambridge Angels, and Women Angels are 5 of 8 investors who have invested in RareCan.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process